The COherence of Scatter Identification and Exclusion Algorithm Study

Recruiting Observational Study
Steatohepatitis, Nonalcoholic
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
15 (estimated)
Sponsor
Institute of Cancer Research, United Kingdom · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040. NAFLD is an unwanted side effect of common cancer therapies, such as chemotherapy. Ultrasound can detect NAFLD via measurement of the backscatter coefficient (BSC). It is an attractive technique because of its low cost and availability…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Healthy Volunteers: * Healthy male or female adults (18 or above). * Volunteers must consider themselves fit and healthy. * RMH and/or ICR employees. Patients: * Patients undergoing liver MRI as part of clinical standard of care with evidence of steatosis on preceding MRI. * …
Contacts

Emma J Harris, PhD

+442087224576

emma.harris@icr.ac.uk

CONTACT